CLINICAL_TRIALS ClinicalTrials.gov record update

Randomized Phase 2 Trial of Ruxolitinib in Combination With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06991101
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:45.073879+00:00
Published At: 2025-12-26T00:00:00+00:00
Record Updated At: 2025-12-26
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Glioblastoma", "Brain Cancer", "Glioblastoma Multiforme", "Glioblastoma Multiforme of Brain", "Glioblastoma Multiforme, Adult", "MGMT-Unmethylated Glioblastoma", "MGMT-Methylated Glioblastoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-26"
protocolSection.identificationModule.nctId: "NCT06991101"
protocolSection.identificationModule.officialTitle: "Randomized Phase 2 Trial of Ruxolitinib in Combination With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma."
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.